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Abstract Background Oncology patients are more at risk
for drug related problems because of treatment with
(combinations of) anticancer drugs, as they have a higher
risk for organ failure or altered metabolism with progres-
sion of their disease. Objective The aim of this study was to
characterize and to evaluate the frequency of potential drug
related problems (pDRPs) among oncology patients. Set-
ting Outpatient- and day-care centres for Internal and
Pulmonary Medicine at the Deventer Hospital, Deventer,
The Netherlands. Method A prospective, descriptive,
observational study was carried out from March 2010 to
March 2011 at the Deventer Hospital, Deventer, The
Netherlands. All patients older than 18 years receiving
anticancer drugs prescribed by an internal medicineoncol-
ogist or pulmonologist-oncologist were included. Main
outcome measure The primary outcome was the number
and type of pDRPs according to Dutch guidelines. Results
Among 546 patients with cancer, 952 pDRPs were identi-
fied, of which 474 were oncology-related. These were
mainly drug interactions (IA) (246 IA in 157 patients) and
potential contraindications (pCI) (201 pCI in 143 patients).
Conclusion Most identified pDRPs in cancer patients were
IAs and pCIs and involved corticosteroids. The most fre-
quently occurring oncology-related IAs were classified as
minor or moderate levels of severity.
Keywords Contraindications  Drug-drug interactions 
Drug-related problems  Oncology  The Netherlands
Impact of findings on practice
• Oncology patients are at high risk for drug-related
problems and therefore need intensive medication
monitoring and counselling.
• The management of cancer is multi-disciplinary. This
can lead to errors in medication information, transfer
and unnoticed potential drug-related problems
(pDRPs). Therefore an actual and accurate patient-
verified list of current medications is a major element in
identifying pDRPs.
• Most of the commonly occurring pDRPs are contrain-
dications (CI) and drug-interactions (IA), mostly
involving corticosteroids.
Introduction
The incidence of cancer has increased over time. In the
Netherlands during 2010, 95,456 new cases of cancer were
identified, an increase of 3.3 % compared with 2009 and of
about 35 % compared with 2000. Of the newly identified
cases in 2010, 42 % were between 60 and 75 years of age
and 31 % over 75 years [1].
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For several reasons, oncology patients in particular need
intensive medication monitoring and counselling. First,
elderly patients often use more drugs as a result of
comorbidities. This increases the risk of drug-related
problems with anticancer drugs in these patients. The use
of anticancer drugs often results in the use of other agents
to reduce or prevent side-effects of the anticancer treat-
ment, thereby increasing the interaction potential [2].
Furthermore, cancer itself increases the need for more
medications. Cytotoxic agents have a narrow therapeutic
window and a complex pharmacologic profile. In oncology
patients, pharmacokinetic parameters can be altered by the
disease itself or due to malnutrition, reduced levels of
serum-binding proteins, oedema, or hepatic and/or renal
dysfunction [3]. Patients with cancer are therefore more at
risk for drug interactions. It has been shown that 20–30 %
of adverse drug reactions can be attributed to drug inter-
actions [2]. Oncology-related PDIs involve between 18 and
58 % of cancer patients [3–5].
The management of cancer is multi-disciplinary. In The
Netherlands, pharmaceutical care for cancer patients is
mostly divided into two channels. Monitoring and dis-
pensing of supportive care agents is performed by the
community pharmacist, generally outside the range of the
hospital, whereas most anticancer drugs, except for oral
formulations, are prepared at the Department of Clinical
Pharmacy and administered on an oncology ward of a
hospital. This can lead to errors in medication information
transfer and unnoticed drug-related problems (DRPs).
Therefore an actual and accurate list of current medications
is a major element in identifying potential DRPs.
Aim of the study
The aim of this study was to characterize and to evaluate




This prospective, descriptive, observational study was
carried out from March 2010 through March 2011 at the
Deventer Hospital, Deventer, The Netherlands. The De-
venter Hospital is a teaching hospital (405 clinical beds)
located in the eastern region of The Netherlands. The
hospital serves a catchment population of about 180,000
residents.
Included were patients older than 18 years receiving
anticancer drugs, including cytotoxic agents, hormones and
biologicals, which were prescribed by a medical oncologist
or pulmonologist-oncologist. Participants were recruited to
the study through an intake appointment with a nurse
oncology consultant. Intake with the nurse oncology con-
sultant took place when a patient was diagnosed with
(relapsed) cancer and could be considered for anticancer
drugs therapy, or prior to change of anticancer drug treat-
ment regimen due to progression. In 2009, 558 oncology
patients had a first appointment with the nurse oncology
consultant prior to treatment with anticancer agents or
before change of treatment regimen.
Patients were excluded from the study if they received
no anticancer drug therapy after intake. Patients gave
written informed consent at the interview or with a returned
list. A declaration of no objection was issued by the Dutch
Central Committee on Research Involving Human Subjects
accredited Medical Ethical Review Board of the Isala
Clinics Zwolle, The Netherlands.
Data collection
All included patients received standard pharmaceutical
care according to Dutch regulatory requirements [6]. For
all patients, on intake with the nurse oncology consultant, a
list of current medications, based on the drug dispensing
history records of the community pharmacy, was made up
and analysed by a pharmacist. The list of current medica-
tions, including identified pDRPs, was provided to the
treating medical oncologist or pulmonologist-oncologist.
Follow-up to identified problems was not part of this study.
Before the intake-appointment with the nurse oncology
consultant, all patients, with the exception of those treated
for lung cancer, received a written invitation for voluntary
participation in a medication reconciliation interview with
a pharmacist. They were asked to send in a self-made list of
current medications by filling out an enclosed blank med-
ication list. Patients treated for lung cancer were excluded
from the medication reconciliation interview at the request
of the pulmonologist, because of their poor prognosis.
Patient characteristics, data on disease and treatment and
laboratory data were obtained from the medical records
database of the hospital. Comorbidities were classified
according to International Statistical Classification of Dis-
eases and Related Health Problems 10th Revision [7].
Classification of DRPs
The potential DRPs in this study were analysed according
to the Shumock-algorithm [8]. Identified potential DRPs
were classified as presented earlier by van den Bemt et al.
[9]. The items categorized as ‘‘therapeutic errors’’ were
considered to be potential DRPs. Oncology-related drug–
drug interactions were assessed according to the consensus
402 Int J Clin Pharm (2013) 35:401–407
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of the Dutch multidisciplinary national expert group on
interactions in oncology [10]. Other drug assessments were
made according to the Dutch National Drug Database (G-
standard) [11]. Both quantify the strength of scientific
evidence (‘‘no evidence’’ through 4 ‘‘controlled, published
interaction studies’’) and clinical significance (A ‘‘Clini-
cally irrelevant effect’’ through F ‘‘Death’’) according to
the same classification system of 6 severity levels [12].
Statistical analysis
Data were collected with the use of MS Excel 2003 and
analysed with the use of MS Access 2003. Each consul-
tation was considered to be a unique unlinked participant.
Descriptive statistics were used to describe patient char-
acteristics, frequency, type and classification of pDRPs.
Results
Patient characteristics
From March 2010 to March 2011, a total of 577 intake-
appointments with 541 patients were made with the nurse
oncology consultant. The inclusion of patients is shown in
Fig. 1. There were 87 intakes with 81 patients who were
diagnosed with lung cancer. At the request of the pulmo-
nologist, patients treated for lung cancer were not invited to
participate in a medication reconciliation interview and
their medications were analysed based on DDHRs alone.
For a total of 392 intakes, patients were reminded to return
their medication list by mail, and 201 (51.3 %) of these
responded. The overall number of intakes per patient was
1.07 (range 1.00–1.08) times. The number of intakes with
the nurse oncology consultant and the number of patients
are considered equal and will further on be referred to as
patients. The patient characteristics are shown in Table 1.
Drug-related problems
A total of 4,618 medication prescriptions were analysed in
which 952 DRPs were identified in 546 patients, including
patients treated for lung cancer, of which 474 (49.8 %)
DRPs were oncology-related. For each patient the best
fitting list of currently used medications was used for
analysis. The identified DRPs are shown in Table 2. The
oncology-related DRPs that we detected were about
equally divided over the categories ‘‘contraindication’’ (CI)
and ‘‘interaction’’ (IA). There were 201 oncology-related
CIs identified in 143 patients in a group of 546 (26.2 %)
patients: 25 CIs could be attributed to an anticancer drug
and 176 to a supportive care agent. There were 246
oncology-related IAs identified at least once in 157 patients
in a group of 546 (28.8 %) patients, of which 26 were IAs
between drugs of the same anticancer drug treatment
regime. Ninety-four IAs could be attributed to an anti-
cancer drug and 152 to a supportive care agent. In 70.4 %
of the cases, oncology-related double medication included
drugs that were part of the chemotherapy regimen, such as
dexamethasone and prednisone. Other classified double
medications included paracetamol (acetaminophen) and
omeprazole. The items for the DRP categories CI and IA
are shown in Tables 3 and 4.
Of the 201 oncology-related CIs, 25 (12.4 %) were a CI
for an anticancer drug and 176 (87.6 %) were a CI for
oncology-related supportive care. The three most identified
oncology-related CIs were hypertension (46.3 %), diabetes
mellitus (22.4 %) and peptic ulcer (6.7 %). All were CIs
Fig. 1 Patient inclusion.
N number of intakes
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with corticosteroids for supportive care. The most identi-
fied CIs for other agents were diabetes mellitus (30.5 %)
and hypertension (16.7 %).
Of the 246 oncology-related IAs, 94 (38.2 %) involved
at least one anticancer drug and 152 (61.8 %) a supportive
care agent. In 56 (22.8 %) of the oncology-related IAs,
coumarins were involved. Coumarins were also involved in
the interaction with the highest level of severity (category
F), an IA with tamoxifen. For the IAs with a supportive
care agent, 65.1 % could be attributed to NSAIDs in
combination with a corticosteroid and 28.3 % to simva-
statin in combination with a corticosteroid.
For IAs with an antineoplastic agent, 79 IAs (84.0 %)
were classified as minor (A and B), 11 IA (11.7 %) as
moderate (D) and 4 IAs (4.3 %) as major (E and F). For
IAs with a supportive care agent, 43 IAs (28.3 %) were
classified as minor (B) and 107 IAs (70.4 %) as moderate
(C and D).
The interacting agents dexamethasone in the IA with
irinotecan or protein kinase inhibitors, both classified as
3A, were part of the anticancer treatment and was con-
sidered to be an intended IA. The IA of the supportive care
drug prednisolone with dexamethasone, classified as 3D,
was an IA between agents that were part of the anticancer
treatment as well. IAs between other drugs in cancer
patients could mainly be attributed to the IA between a
renin-angiotensin system (RAAS) inhibitor and a diuretic
(17.5 %) and between a RAAS-inhibitor and an NSAID
(8.5 %).
Discussion
In this study, most CIs with an anticancer drug involved
fluoropyrimidines and most CIs with a supportive care
agent involved corticosteroids. However, all CIs, i.e. co-
morbidities, were adequately managed, and, as a conse-
quence, were not considered to be of clinical relevance.
Most IAs related to the use of supportive care drugs were
classified as moderate (70.4 %). The most frequently
identified IA with a supportive care drug was a
Table 1 Characteristics of patients in the study
Inclusion
Number of patients 510




Intakes per patient 1.07
Sex
Male 238 (43.6 %)
Female 308 (56.4 %)
Age in years
Mean ± SD 63.7 ± 12.0
Type of cancer
1. Gastrointestinal 172 (31.5 %)
2. Breast 146 (26.7 %)
3. Haematological 62 (11.4 %)
4. Lung 87 (15.9 %)
5. Urologic 36 (6.6 %)
6. Other 43 (7.9 %)
Treatment intent
Curative/adjuvant 248 (45.4 %)
Palliative 298 (54.6 %)
Cancer treatment
Chemotherapy 408 (74.7 %)
Hormonal therapy 1 (0.2 %)
Molecular therapy 42 (7.7 %)
Combinations 95 (17.4 %)
Drugs
MOs 9 total 4,618
Mean no. of drugs ± SD 8.5 ± 3.7
MOs oncolytics 1154 (25.0 %)
Mean no. of oncolytics ± SD 2.1 ± 0.9
MOs supportive care drugs 897 (19.3 %)
Mean no. of supportive care drugs ± SD 1.6 ± 1.0
MOs other drugs 2573 (55.7 %)
Mean no. of other drugs ± SD 4.7 ± 3.4
Follow-up (3 months)
Died 52 (9.5 %)
MOs medication orders
Table 2 Analysed DRPs among cancer patients
Oncology related DRPs 474
Contraindication 201 (42.4 %)
Contraindication per patient ± SD 0.4 ± 0.7
Patients with C1 contraindication 143 (26.2 %)
Interaction 246 (51.9 %)
Interaction per patient ± SD 0.5 ± 0.9
Patients with C1 interaction 157 (28.8 %)
Unjustified mono-therapy 0 (0.0 %)
Double medication 27 (5.7 %)
Other DRPs 478
Contraindication 246 (51.5 %)
Contraindication per patient ± SD 0.5 ± 1.1
Patients with C1 contraindication 117 (21.4 %)
Interaction 177 (37.0 %)
Interaction per patient ± SD 0.3 ± 0.9
Patients with C1 interaction 100 (18.3 %)
Unjustified mono-therapy 2 (0.4 %)
Double medication 53 (11.1 %)
404 Int J Clin Pharm (2013) 35:401–407
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corticosteroid with a NSAID (65.1 %). However, in 68 of
the 99 (68.7 %) cases, a proton pump inhibitor was already
prescribed, a required action to reduce the risk of peptic
ulcer, or the use of the NSAID was not chronic.
Although there are methodological differences, the five
most identified oncology-related IAs by this study are in
agreement with those identified by Riechelmann et al. [3]
as well as those identified by Van Leeuwen et al. [5]. Our
study results are dissimilar to those of Voll et al. [4],
because of a high percentage of antiretroviral drugs pre-
scriptions in their patients, causing specific IAs. Both
Riechelmann et al. and Van Leeuwen et al. used The Drug
Interactions Facts [13] as a drug-interaction-database
whereas in this study the Dutch national drug database
[11], including the consensus-based management of anti-
cancer drug interactions, was used [10]. Van Leeuwen et al.
found a higher percentage of patients with IAs with anti-
cancer drugs: 138 IAs occurring at least once in 161
patients in a group of 278 (58 %) patients. This is mainly
due to the inclusion of IAs (classified by the authors as
major) with potential QT-interval prolongation and/or
torsades de pointes-inducing properties according to the
Table 3 Contraindications involving anticancer, supportive and other agents
Agent Contraindication Effect n
Anticancer agent
Fluoropyrimidines Angina pectoris Capecitabine, fluorouracil and tegafur can trigger
attacks of angina pectoris
5
Capecitabine Decreased renal function Increased level of capecitabine 5
Carboplatin Decreased renal function Increased level of carboplatine 4
Rituximab Heart failure Increase of heart failure 3
Cyclophosphamide/Iphosphamide Heart failure Increase of heart failure 2
Anthracycline derivates Heart failure Increase of heart failure 2
Cisplatin Decreased renal function Nephrotoxic 1
Capecitabine Liver function disorder Increased serum level of capecitabine 1
Epirubicin Liver function disorder Increased serum level of epirubicin 1
Etoposide Decreased renal function Increased serum level of etoposide 1
Supportive care agent
Corticosteroid Hypertension Corticosteroids can induce hypertensiona 93
Glucocorticosteroid Diabetes Mellitus Increased level of serum glucose 45
Glucocorticosteroid Peptic Ulcer Glucocorticosteroids can induce an ulcus pepticum 14
Corticosteroid Depression Corticosteroids can induce and increase depressionb 11
Metoclopramide Decreased renal function Increased level of serum metoclopramide 5
Corticosteroid Psoriasis Psoriasis can aggravate after stop with corticosteroid 5
Glucocorticosteroid Glaucoma Glucocorticosteroids can induce glaucoma 2
Metoclopramide Epilepsy Metoclopramide can trigger an epileptic attack 1
Other agentc
RAAS-inhibitor Diabetes mellitus Decreased serum glucose level 28
Selective beta blocker Diabetes mellitus Cover symptoms of low serum glucose level and
inhibit recovery
26
Antithrombotic Hypertension Increased risk of cerebral haemorrhage 23
Selective beta blocker Asthma/COPD Bronchoconstriction at higher dose 13
Thiazides Diabetes mellitus Increased level of serum glucose 10
Opioids Asthma/COPD Dose-dependent breath reduction 9
Loop diuretic/thiazides Gout Increase of gout attack 7
Salicylates Peptic Ulcer Increased risk of peptic ulcer 7
Loop diuretic Hyperplasia of prostate Acute urine retention 7
Opioids Hyperplasia of prostate Urine retention 7
a Especially at high doses (C20 mg prednisone/day and equivalent doses)
b Especially at high doses (C40 mg prednisone/day and equivalent doses)
c For other agents the 10 most frequently identified CI are reported
Int J Clin Pharm (2013) 35:401–407 405
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Arizona-list [14]. These QT IAs in the study by Van
Leeuwen are responsible for almost one-third of the IAs
found.
On behalf of the pulmonologist, patients treated for lung
cancer were not invited for voluntary participation. The
number of patients treated for lung cancer in this study,
about 15 %, is substantial. In general, patients treated for
lung cancer are more ill and have a worse prognosis as
compared with breast and/or colon cancer (the two most
commonly occurring types of cancer). In our opinion,
patients treated for lung cancer should therefore not be
excluded from the descriptive analysis of occurring pDRPs
despite the fact that their medications were analysed only
based on DDHRs.
Table 4 Interactions involving anticancer and supportive agents
Agent Interacting agent Effect Classa n
Anticancer agent
Cytostatic agent Coumarins Altered coagulation time 1B 56
Irinotecanb Dexamethasone Decreased serum level of irinotecan 3A 15
PKI Dexamethasone Decreased serum level of PKI 3A 4
Variousc Valproic acid Therapeutic failure of valproic acid 2D 4





Therapeutic failure of anti-epileptic drug 2D 3
PKI Secretion inhibitor Decrease of bioavailability of PKI 1A 3
Variousc Phenytoin Therapeutic failure of phenytoin 3D 2
Variousc Carbamazepine Therapeutic failure of carbamazepine 2D 2
Tamoxifen Coumarins Increased coagulation time 1F 1
Imatinib Statin Increased risk of myopathy 3A 1
Supportive care agent
Corticosteroid NSAID (excl. COXIB) Increased risk of peptic ulcer 3C 99
Dexamethasone Simvastatin/atorvastatin Decreased serum level of simvastatin, atorvastatin
and active metabolites
3B 43
Dexamethasone Prednisolone Decreased serum level of dexamethasone 3D 7
Aprepitant Coumarins Coagulation time decreases – 2
Antiemetic Ropinirole Counteracting effect 2D 1
Other agentsd
RAAS-inhibitor Diuretic Once only sudden decrease of blood pressure
when RAAS-inhibitor is added to diuretic
3D 31
RAAS-inhibitor NSAID Decreased action of RAAS-inhibitor 3D 15
Beta blocker NSAID Decreased action of beta blocker 3C 15
Alpha blocker Beta blocker/calcium antagonist Once only sudden decrease of blood pressure when
alpha blocker is added to beta blocker/calcium
antagonist
3B 14
Beta blocker Oral antidiabetic Increased effect of hypoglycaemia and inhibit recovery 3B 14
Beta blocker selective Insulin Increased effect of hypoglycaemia and inhibit recovery 3B 11
Diuretic NSAID Therapeutic failure of diuretic 3D 10
Coumarin (Es)omeprazol Increased effect of coumarin 1D 9
Bisphosphonate Antacid/iron/calcium Decreased absorption of bisphosphonate at simultaneous
intake
0A 7
Salicylate (antithrombotic) NSAID (excl. ibuprofen) Increased risk of bleeding ulcer 3C 5
COXIB cyclo-oxygenase-2 inhibitor, PKI protein kinase inhibitor
a Classification of levels of severity and evidence by documentation of oncology related drug interactions [13]
b Combination of irinothecan and dexamethasone within the same treatment protocol is regarded as an intended drug interaction. All reported IA
are the result of intended combination within the treatment protocol
c Cisplatin, cyclophosphamide, doxorubicin, etoposide, iphosphamide, methotrexate, paclitaxel
d For other agents the 10 most frequently identified CI are reported
406 Int J Clin Pharm (2013) 35:401–407
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Conclusion
We showed a high prevalence of identified oncology-
related DRPs in cancer patients. The DRPs involved are
mainly contraindications (CIs) and drug interactions (IAs).
There were 201 oncology-related CIs identified in 143
patients in a group of 546 (26.2 %) patients: 25 CIs could
be attributed to an anticancer drug and 176 to a supportive
care agent. Most CI with an anticancer drug involved flu-
oropyrimidines and most CIs with a supportive care agent
involved corticosteroids. There were 246 oncology-related
IAs identified at least once in 157 patients in a group of 546
(28.8 %) patients, of which 26 were IAs between drugs of
the same anticancer drug treatment. For IAs with an anti-
neoplastic agent, 79 IAs (84.0 %) were classified as minor
(A and B), 11 IAs (11.7 %) as moderate (D), and 4 IAs
(4.3 %) as major (E and F). For IAs with a supportive care
agent, 43 IAs (28.3 %) were classified as minor (B) and
107 IAs (70.4 %) as moderate (C and D).
Commonly occurring pDRPs are CIs and IAs, mostly
involving corticosteroids, and are of a minor or moderate
level of clinical significance.
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